Long-term lamivudine therapy for chronic hepatitis b infection in children unresponsive to interferon

Journal of Pediatric Gastroenterology and Nutrition

Volumn 43, Issue 4, 2006, Pages 494-498

  Hartman, Corina ^a   Berkowitz, Drora ^a   Eshach Adiv, Orly ^a   Hino, Bian ^a   Rimon, Nurit ^b   Satinger, Iehudith ^b   Kra Oz, Tzipi ^b   Shamir, Raanan ^a  

^a MEYER CHILDREN S HOSPITAL   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Children; Chronic hepatitis B; Lamivudine; Long term therapy

Indexed keywords

CREATINE KINASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HEPATITIS B; HUMAN; LONG TERM CARE; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SCHOOL CHILD; SEROCONVERSION;

ADOLESCENT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CHILD; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS; LAMIVUDINE; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT REFUSAL; VIRAL LOAD;

EID: 33749996503     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mpg.0000235982.34323.67     Document Type: Article

References (23)

1. Bortolotti F, Calzia R, Vegnente A, et al. Chronic hepatitis in childhood: the spectrum of the disease. Gut 1988;29:659-64.
2. Di Marco V, Lo Iacono O, Camma C, et al. The long-term course of chronic hepatitis B. Hepatology 1999;30:257-64.
3. Sokal EM, Conjeevaram HS, Roberts EA, et al. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 1998;114:988-95.
4. Jonas MM, Mizerski J, Badia IB, et al. International Pediatric Lamivudine Investigator Group. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002;346:1706-13.
5. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63.
6. Dienstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61.
7. Santantonio T, Mazzola M, Iacovazzi T, et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000;32:300-6.
8. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119:172-80.
9. Leung NW, Lai CL, Chang TT, et al. On behalf of the Asia Hepatitis Lamivudine Study Group. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32.
10. Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J Gastroenterol Hepatol 2004;19:1276-82.
11. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-22.
12. Liaw YF, Chien RN, Yeh CT, et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-72.
13. Sokal EM, Kelly DA, Mizerski J, et al. Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B. Hepatology 2006;43:225-32.
14. Ozgenc F, Arikan C, Sertoz RY, et al. Effect of long-term lamivudine in chronic hepatitis B virus-infected children. Antivir Ther 2004t;9:729-32.
15. Hartman C, Berkowitz D, Shouval D, et al. Lamivudine treatment for chronic hepatitis B infection in children unresponsive to interferon. Pediatr Infect Dis J 2003;22:224-9.
16. Stuyver LJ, Locarnini SA, Lok A, et al. The HEP DART International Committee Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001;33:751-7.
17. Heermann KH, Gerlich WH, Chudy M, et al. Quantitative detection of hepatitis B virus DNA in two international reference plasma preparations. J Clin Microbiol 1999;37:68-73.
18. Allen MI, Gauthier J, DesLauriers M, et al. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microbiol 1999; 37:3338.
19. Doong S, Tsai C, Schinazi R, et al. Inhibition of the replication of hepatitis B virus in vitro by 2,3-dideoxy-3-thiacytidine and related analogues. Proc Natl Acad Sci U S A 1991;88:8495-9.
20. Locarnini S. Molecular virology of hepatitis B virus. Semin Liver Dis 2004;24:3-10.
21. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003;124: 105-17.
22. Chayama K, Suzuki Y, Kobayashi M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998;27:1711-6.
23. Yahagi K, Ueno Y, Mano Y, et al. Rhabdomyolytic syndrome during the lamivudine therapy for acute exacerbation of chronic type B hepatitis. Liver Transpl 2002;8:1198-9.